Joel Latham is the CEO and Managing Director of Incannex Healthcare and is responsible for the Company's commercial operations, strategic decision-making, and oversight of all clinical development assets. Joel is widely experienced in management and operational matters, with 14 years experience with major firms such as Mars Foods, Tabcorp and Philip Morris International. He has been pivotal in the development and execution of Incannex’s drug development and regulatory strategy.

Troy Valentine has been Chairman of the Board of Directors since December 2017. Troy is a finance professional with extensive managerial and Board experience. He has significant corporate and capital raising experience, especially with start-ups and small to mid-cap size companies. He is currently a director of Australian boutique corporate advisory firm Alignment Capital Pty Ltd, which he co-founded in 2014.

Dr Sud Agarwal has been the Chief Medical Officer of Incannex since June 2019, responsible for conceptualizing the Company’s pipeline of proprietary cannabinoid products and regulatory strategies.

Peter Widdows is a Fellow Chartered Accountant with extensive experience in Australian and international consumer goods markets, and has worked as a senior executive in numerous countries around the world, including Europe, US and Asia Pac. including a role as the Regional Chief Executive Officer — Australasia and Greater China at the H. J. Heinz Company. Peter is also the Chairman of Sunny Queen Australia Ltd, and is also a Non-Executive Director of Youi Insurance Holdings Ltd.

Madhukar “Madhu” is an experienced company secretary who has previously worked with multiple ASX-listed companies and is proficient in corporate governance, company administration, financial management and corporate law. Madhu also has significant business and management experience including roles as general manager and corporate administrator. Madhu was the managing director of Colortype Press for a period of 8 years where he was responsible for the overall management of the business.

Dr Bleackley has a PhD in Genetics from the University of British Columbia with post-doctoral training at La Trobe University and Australian biotechnology company Hexima Ltd. As Chief Scientific Officer, he oversees all research and development activities at Incannex, from proof-of-concept to commercialisation.

Rosemarie Walsh has a degree in Applied Biology from RMIT University and over 20 year’s experience in clinical trials including concept/design, start-up, conduct and close out, having worked for global and local contract research organizations and global pharma. As clinical research manager, Rosemarie oversees all aspects of Incannex’s clinical trials.

Pia Kroner is the Clinical Research Coordinator at Incannex Healthcare Limited working on design and development of clinical trials for Incannex's new drugs. She has a bachelor's degree in Biomedical Science with Honours from La Trobe University and experience in running phase I clinical trials in the clinical unit.